Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Ester, Del Signore"'
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Gloria Pellizzari, Jalissa Katrini, Antonio Passaro, Filippo de Marinis
Publikováno v:
Cancers, Vol 16, Iss 16, p 2877 (2024)
RET fusions are relatively rare in Non-Small-Cell Lung Cancers (NSCLCs), being around 1–2% of all NSCLCs. They share the same clinical features as the other fusion-driven NSCLC patients, as follows: younger age, adenocarcinoma histology, low exposu
Externí odkaz:
https://doaj.org/article/97a2e624922d4c4f87cafc8b8147cc86
Autor:
Ilaria Attili, Riccardo Asnaghi, Davide Vacirca, Riccardo Adorisio, Alessandra Rappa, Alberto Ranghiero, Mariano Lombardi, Carla Corvaja, Valeria Fuorivia, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Gianluca Spitaleri, Ester Del Signore, Juliana Guarize, Lorenzo Spaggiari, Elena Guerini-Rocco, Nicola Fusco, Filippo de Marinis, Antonio Passaro
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 15, p 4476 (2024)
Background: Actionable driver mutations account for 40–50% of NSCLC cases, and their identification clearly affects treatment choices and outcomes. Conversely, non-actionable mutations are genetic alterations that do not currently have established
Externí odkaz:
https://doaj.org/article/5e92df69925744f4959588ed02b29765
Autor:
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro, Filippo de Marinis
Publikováno v:
Cancers, Vol 16, Iss 14, p 2589 (2024)
Background: Platinum-based chemotherapy is the current standard treatment option in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who progress on osimertinib. However, outcomes with chemotherapy are dismal, and the treatment of central
Externí odkaz:
https://doaj.org/article/c7ab8ff0683842dcb86208dd48ea1061
Autor:
Ilaria Attili, Valeria Fuorivia, Gianluca Spitaleri, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, Riccardo Asnaghi, Ambra Carnevale Schianca, Antonio Passaro, Filippo de Marinis
Publikováno v:
Cancers, Vol 16, Iss 13, p 2457 (2024)
Various next-generation ALK TKIs are available as first-line options for ALK-positive NSCLC, with alectinib and lorlatinib being commonly preferred. However, no direct comparison between them has been conducted, making it impossible to pick a winner.
Externí odkaz:
https://doaj.org/article/e39dfd309c2c4cfda88b8f8ec72914e1
Autor:
Pamela Trillo Aliaga, Ester Del Signore, Valeria Fuorivia, Gianluca Spitaleri, Riccardo Asnaghi, Ilaria Attili, Carla Corvaja, Ambra Carnevale Schianca, Antonio Passaro, Filippo de Marinis
Publikováno v:
Genes, Vol 15, Iss 6, p 701 (2024)
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma accounting for 15% of lung cancers with dismal survival outcomes. Minimal changes in therapy and prognosis have occurred in SCLC for the past four decades. Recent progress in the
Externí odkaz:
https://doaj.org/article/cb99cc0e1f1d4a489f82cfd55b51442e
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5072-5092 (2023)
ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK
Externí odkaz:
https://doaj.org/article/237f3ac30475444a97d7a0d94817d83b
Autor:
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Ester Del Signore, Pamela Trillo Aliaga, Antonio Passaro, Filippo de Marinis
Publikováno v:
Cancers, Vol 15, Iss 20, p 5079 (2023)
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring most driver gene alterations. Starting from the first generation, research rapidly moved to the develo
Externí odkaz:
https://doaj.org/article/4b8767c369a746daa0fdd2eb0f0f8c68
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Jacopo Uliano, Antonio Passaro, Filippo de Marinis
Publikováno v:
Cancers, Vol 15, Iss 19, p 4779 (2023)
Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET gene amplification (MET AMP), or MET gene mutations. Retrospective studies of surgical series of patients with MET-dysregulated NSCLC h
Externí odkaz:
https://doaj.org/article/90847ff7dadf4c7886b63ffcc5e1eb26
Autor:
Ilaria Attili, Carmine Valenza, Celeste Santoro, Gabriele Antonarelli, Pamela Trillo Aliaga, Ester Del Signore, Chiara Catania, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundFollowing the introduction of immunotherapy (IO) in the first-line (1L) treatment in patients with non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK mutations, increasing real-world data depict how difficult it is to replicate
Externí odkaz:
https://doaj.org/article/b82967c179b1415b8e47bb150aadac48
Publikováno v:
Patient Experience Journal (2020)
When you get ill, the first thing that comes to your mind is, “Will I make it? Will I survive?". COVID19 has a major impact on mental health. A sadness that inundates us like a river in flood and which we cannot hold back. But the thing that tormen
Externí odkaz:
https://doaj.org/article/6de39efdeea945b7a0fb961d07e4b4dd